AT-527 Chemical Properties

storage temp. 

Store at -20°C

solubility 

DMSO : 180 mg/mL (285.45 mM; Need ultrasonic)

form 

Solid

color 

White to off-white

InChIKey

MKBNJIGFOVMYRL-DBENCIMWNA-N

SMILES

S(O)(O)(=O)=O.C[C@]1([C@@H]([C@@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)OC2C=CC=CC=2)O[C@H]1N1C=NC2=C(N=C(N)N=C12)NC)O)F |&1:6,7,8,14,30,r|

AT-527 Usage And Synthesis

Uses

Bemnifosbuvir hemisulfate (AT-527), a hemisulfate salt of AT-511, a guanosine nucleotide proagent, is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3].

in vivo

References

[1] Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104. DOI:10.1371/journal.pone.0227104
[2] Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8;AAC.02479-20. DOI:10.1128/AAC.02479-20
[3] Elina Berliba, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30;63(12):e01201-19. DOI:10.1128/AAC.01201-19